<DOC>
	<DOCNO>NCT02027662</DOCNO>
	<brief_summary>Phosphate binder crucial control elevate phosphate level patient chronic kidney disease . With new formulation granule pill burden patient seek reduce . This study efficacy safety new drug formulation compare `` old '' formulation film-coated tablet .</brief_summary>
	<brief_title>Therapeutic Equivalence OsvaRen® Tablets OsvaRen® Granules</brief_title>
	<detailed_description>The study aim demonstrate therapeutic equivalence product , i.e . granule versus tablet . Secondary objective : Comparing preparation regard number patient reach serum phosphate level &lt; 1.76 mmol/L difference serum phosphate level first last visit treatment . Furthermore , aim study evaluate safety profile OsvaRen® granules comparison OsvaRen® tablet . Especially serum calcium , magnesium , PTH interest .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Signed write informed consent form obtain prior start screen visit Male female patient 1880 year age dialysis dependent renal failure ( CKD 5D ) Patients 3x/week incentre renal replacement therapy least 2 month either lowflux highflux HD OL /HDF Prescribed haemodialysis session duration ≥ 4 hour spKt/V ≥ 1.20 accord last incentre measurement prior study enrolment Patients OsvaRen® tablet least 12 week sole phosphate binder titration phase complete accord physician´s discretion Patients able take study medication prescribe particularly OsvaRen® stickpacks Patients willing stop calcium , magnesium vitamin D contain supplement Patients willing maintain typical diet regard phosphate uptake time study Patients willing comply study protocol Exclusion criterion Pregnant woman ( blood ßhCG pregnancy test ) woman breastfeed unwilling use contraceptive measure entire course study Patients life expectancy shorter plan duration study Patients acute chronic severe disease potentially interfere study outcome Patients PTH level &gt; 800 ng/l Patients participate interventional clinical study precede 30 day Patients suffer , mention condition could interfere patient 's ability comply study Patients previously participate study exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>